FDA Eases Up On Part 11 Scope, Pulls Old Guidelines
This article was originally published in The Gray Sheet
Executive Summary
FDA will scale back enforcement of its electronic records and signatures rule (Part 11) for all FDA-regulated products while it reassesses the regulation in light of the agency's current good manufacturing practice initiative for drugs and biologics
You may also be interested in...
On The Virtual Horizon? FDA Revising Software Guidance, Part 11 Policy
Stakeholders will have an opportunity to comment on FDA's evolving policy on Part 11 electronic records regulation during a June meeting
On The Virtual Horizon? FDA Revising Software Guidance, Part 11 Policy
Stakeholders will have an opportunity to comment on FDA's evolving policy on Part 11 electronic records regulation during a June meeting
Part 11 Audit Trails, Legacy Systems Subject To FDA Enforcement Discretion
Device manufacturers must continue to validate electronic recordkeeping and signature systems under ongoing FDA part 11 enforcement discretion, according to CDRH International Staff Director Christine Nelson